{"id":"W4249938708","doi":"10.1158/1538-7445.sabcs18-ct158","title":"Abstract CT158: ATHENA (GOG-3020/ENGOT-ov45): a randomized, double-blind, placebo-controlled, Phase III study of rucaparib + nivolumab following front-line platinum-based chemotherapy in ovarian cancer","year":2019,"lang":"en","type":"article","venue":"Clinical Trials","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Ovarian cancer; Nivolumab; Oncology; Placebo; Double blind; Chemotherapy; Internal medicine; Front line; Cancer; Immunotherapy; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaresearch","metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.03407102,0.000724853,0.009766722,0.0004856767,0.0000929258,0.00006310442,0.0004499661,0.0007075239,0.005078499],"category_scores_gemma":[0.004513682,0.0005578664,0.002716402,0.0004953641,0.0002435566,0.0001989152,0.00004829005,0.001203894,0.0001078822],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003238413,"about_ca_system_score_gemma":0.001213568,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00125411,"about_ca_topic_score_gemma":0.0002574472,"domain_scores_codex":[0.9855697,0.002976221,0.008271399,0.001260348,0.001181591,0.0007407995],"domain_scores_gemma":[0.9785153,0.01620492,0.003195172,0.001358359,0.0002898479,0.0004363903],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9705576,0.008660137,0.004377664,0.0001002005,0.003161559,0.00005693956,0.001020223,0.0005655075,0.004830905,0.00003781143,0.0005362217,0.006095231],"study_design_scores_gemma":[0.9880661,0.002464092,0.0003560325,0.0009393637,0.001235023,0.000002399139,0.0004683077,0.002346435,0.002845381,0.0002147553,0.0005449551,0.0005171933],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9687488,0.001125865,0.0007248637,0.001519161,0.002786578,0.02336315,0.00007359184,0.0001178952,0.001540062],"genre_scores_gemma":[0.9923868,0.000329878,0.0005876992,0.001393121,0.001803051,0.002553928,0.00006414561,0.0001347055,0.0007466506],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.02955734,"threshold_uncertainty_score":0.9996873,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1940413944317502,"score_gpt":0.4964910619994237,"score_spread":0.3024496675676735,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}